These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 23525426

  • 1. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.
    J Am Heart Assoc; 2013 Jan 28; 2(1):e003277. PubMed ID: 23525426
    [Abstract] [Full Text] [Related]

  • 2. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H.
    Cardiovasc Diabetol; 2014 Jul 30; 13():110. PubMed ID: 25074318
    [Abstract] [Full Text] [Related]

  • 3. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H, FESC, for Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy (3D) study investigators.
    Cardiovasc Diabetol; 2015 Jun 19; 14():83. PubMed ID: 26084668
    [Abstract] [Full Text] [Related]

  • 4. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168
    [Abstract] [Full Text] [Related]

  • 5. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME, Puppala VK, Suboc TM, Malik M, Branum A, Signorelli K, Wang J, Ying R, Tanner MJ, Tyagi S.
    Vasc Med; 2017 Jun 13; 22(3):189-196. PubMed ID: 28145158
    [Abstract] [Full Text] [Related]

  • 6. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.
    Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R, Takahashi H.
    Cardiovasc Diabetol; 2016 Nov 04; 15(1):153. PubMed ID: 27809903
    [Abstract] [Full Text] [Related]

  • 7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.
    J Clin Endocrinol Metab; 2006 Nov 04; 91(11):4612-9. PubMed ID: 16912128
    [Abstract] [Full Text] [Related]

  • 8. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
    Fujita H, Taniai H, Murayama H, Ohshiro H, Hayashi H, Sato S, Kikuchi N, Komatsu T, Komatsu K, Komatsu K, Narita T, Yamada Y.
    Endocr J; 2014 Nov 04; 61(2):159-66. PubMed ID: 24225429
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 04; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.
    Drug Des Devel Ther; 2013 May 04; 7():989-1001. PubMed ID: 24068868
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K, SUCCESS Study Group.
    Diabetes Obes Metab; 2014 Aug 04; 16(8):761-5. PubMed ID: 24447683
    [Abstract] [Full Text] [Related]

  • 12. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ.
    Curr Med Res Opin; 2009 Oct 04; 25(10):2507-14. PubMed ID: 19691426
    [Abstract] [Full Text] [Related]

  • 13. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.
    Cardiovasc Drugs Ther; 2018 Feb 04; 32(1):73-80. PubMed ID: 29435776
    [Abstract] [Full Text] [Related]

  • 14. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S.
    Cardiovasc Diabetol; 2020 Jun 15; 19(1):89. PubMed ID: 32539832
    [Abstract] [Full Text] [Related]

  • 15. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ.
    J Am Heart Assoc; 2014 Aug 26; 3(4):. PubMed ID: 25158865
    [Abstract] [Full Text] [Related]

  • 17. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
    Kishimoto S, Kinoshita Y, Matsumoto T, Maruhashi T, Kajikawa M, Matsui S, Hashimoto H, Takaeko Y, Kihara Y, Chayama K, Goto C, Mohamad Yusoff F, Nakashima A, Noma K, Higashi Y.
    Am J Hypertens; 2019 Jun 11; 32(7):695-702. PubMed ID: 31045223
    [Abstract] [Full Text] [Related]

  • 18. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 11; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 19. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI, Cabrera A, Charron D.
    Ann Pharmacother; 2013 Nov 11; 47(11):1532-9. PubMed ID: 24285765
    [Abstract] [Full Text] [Related]

  • 20. Effects of sitagliptin beyond glycemic control: focus on quality of life.
    Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K, S-DOG investigators.
    Cardiovasc Diabetol; 2013 Feb 21; 12():35. PubMed ID: 23432786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.